Onkure Therapeutics Inc
NASDAQ: OKURBoulder, US · Founded 2014 · Delaware corporation · 42 employees on LinkedIn · 6 known investors
OnKure Therapeutics is a clinical-stage biopharmaceutical company developing PI3Kα pan-mutant selective inhibitor medicines for the treatment of breast cancer and vascular anomalies. Its focus is on selective, allosteric small-molecule oncology therapeutics.
Founders & leadership
JL
Jason LeveroneExecutive
SA
Samuel AgrestaExecutive
DH
Dylan HartleyExecutive
NS
Nicholas SaccomanoExecutive
WJ
Wendy JohnsonExecutive
Board
IM
ET
NO
VM
Valerie M. JansenBoard director
RM
R. Michael CarruthersBoard director
MG
Michael G. GreyBoard director
AJ
Andrew Johm PhillipsBoard director
Investors · 6
Access BiotechnologyNew York City
RiverVest Venture PartnersSt. Louis · $500K – $3M
AbingworthreportedLondon · $15M – $30Mvia Bali Muralidhar · board
ACORN BIOVENTURESreportedNew Yorkvia Isaac Manke · board
Boulder VenturesreportedBoulder · $1M – $4M
New Enterprise Associates (NEA)reportedMenlo Park · $200K – $40M
Reported raises · per SEC filings
Form D private placements$159.4M disclosed across 4 rounds · 2017–2024
▶$65MraisedOct 2024 · 20 investors · PharmaceuticalsRule 506(b)
▶$65MraisedOct 2024 · 20 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Isaac MankeDirector
- Jason LeveroneExecutive Officer
- Samuel AgrestaExecutive Officer
- Dylan HartleyExecutive Officer
- Edward T. MathersDirector
- Nicholas SaccomanoExecutive Officer, Director
- Valerie M. JansenDirector
- R. Michael CarruthersDirector
- Michael G. GreyDirector
- Andrew Johm PhillipsDirector
- Offering amount
- $65M
- Amount sold
- $65M
- Sales commissions
- $3.3M
- Placement agents
- LifeSci Capital, LLC, Leerlink Partners LLC, Evercore Group, L.L.C
- First sale
- Oct 2024
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$47.4MraisedDec 2020 · 15 investors · PharmaceuticalsRule 506(b)
▶$47.4MraisedDec 2020 · 15 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Gregory FlesherExecutive Officer, Director
- Lon Cardon, Ph.D.Director
- Michael GreyDirector
- Johan Kordel, Ph.D.Director
- Ed MathersDirector
- Niall O'Donnell, Ph.D.Director
- Wendy JohnsonExecutive Officer
- Alejandro Dorenbaum, M.D.Executive Officer
- Kenneth HarrisonDirector
- Bali MuralidharDirector
- Stacey SeltzerDirector
- Mike CruseExecutive Officer
- Offering amount
- $94.8M
- Amount sold
- $47.4M
- First sale
- Dec 2020
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$25MraisedMay 2019 · 9 investors · PharmaceuticalsRule 506(b)
▶$25MraisedMay 2019 · 9 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Michael GreyDirector
- Niall O'Donnell, Ph.D.Executive Officer, Director
- Lon Cardon, Ph.D.Director
- Ed MathersDirector
- Johan Kordel, Ph.D.Director
- Art PappasDirector
- Wendy JohnsonExecutive Officer
- Alejandro Dorenbaum, M.D.Executive Officer
- Offering amount
- $25M
- Amount sold
- $25M
- First sale
- May 2019
- Incorporated
- Corporation, Delaware, 2014
- Federal exemptions
- 06b
▶$22MraisedJan 2018 · 16 investors · PharmaceuticalsRule 506(b)
▶$22MraisedJan 2018 · 16 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Scott WeinerDirector
- Wendy JohnsonExecutive Officer
- Michael GreyExecutive Officer, Director
- Niall O'DonnellExecutive Officer, Director
- Ed MathersDirector
- Offering amount
- $52M
- Amount sold
- $22M
- First sale
- Dec 2017
- Incorporated
- Corporation, Delaware, 2014
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Competitors · 3
by search overlap
Kura Oncology43 shared keywordsKura Oncology is a company in the oncology/medtech sector that provides grant support for independent medical education programs designed to enhance healthcare professionals' ability to diagnose and treat patients in Kura Oncology's therapeutic areas of interest.
NovoCure42 shared keywordsNovocure is a global oncology company developing Tumor Treating Fields therapies, including its Optune Pax device, to treat aggressive cancers such as locally advanced pancreatic cancer. It serves cancer patients and their treating physicians in the medical device and healthcare sector.
Bioworld37 shared keywordsBioWorld is a suite of daily news and data services covering therapeutics, medical technology, biopharma business transactions, and drug R&D, serving biopharmaceutical and medtech industry professionals. Owned by Clarivate, it publishes products including BioWorld, BioWorld Science, and BioWorld Asia with reporting from writers stationed globally.
Companies competing with Onkure Therapeutics Inc for the same Google search keywords, organic and paid, via search-intersection analysis.
Frequently asked questions
- What does Onkure Therapeutics Inc do?
- OnKure Therapeutics is a clinical-stage biopharmaceutical company developing PI3Kα pan-mutant selective inhibitor medicines for the treatment of breast cancer and vascular anomalies. Its focus is on selective, allosteric small-molecule oncology therapeutics.
- Who are Onkure Therapeutics Inc's investors?
- Onkure Therapeutics Inc's investors include Access Biotechnology, RiverVest Venture Partners, Abingworth, ACORN BIOVENTURES, Boulder Ventures, New Enterprise Associates (NEA).
- How much funding has Onkure Therapeutics Inc raised?
- Onkure Therapeutics Inc has disclosed $159.4M raised across 4 rounds.
- Where is Onkure Therapeutics Inc headquartered?
- Onkure Therapeutics Inc is headquartered in Boulder, US.